Table A2.
Concomitant non-lipid lowering therapies.
| Concomitant Drugs | N (%) |
|---|---|
| Beta-blockers | |
| - Bisoprolol | 53 (40.8) |
| - Nebivolol | 7 (5.4) |
| - Metoprolol | 6 (4.6) |
| - Carvedilol | 5 (3.8) |
| - Atenolol | 3 (2.3) |
| Antiplatelet agents | |
| - Acetylsalicylic acid | 49 (37.7) |
| - Clopidogrel | 9 (6.9) |
| - Ticagrerol | 13 (10) |
| - Clopidogrel + acetylsalicylic acid | 19 (14.6) |
| ACE- inhibitors | |
| - Ramipril | 30 (23.1) |
| - Lisinopril | 6 (4.6) |
| - Enalapril | 5 (3.8) |
| Angiotensin II receptor-blockers | |
| - Losartan | 9 (6.9) |
| - Olmesartan | 11 (8.5) |
| - Telmisartan | 7 (5.4) |
| - Valsartan | 6 (4.6) |
| Calcium channel-blockers | |
| - Amlodipine | 14 (10.8) |
| - Lercandipine | 1 (0.8) |
| Diuretics | |
| - Thiazide diuretics | 17 (13) |
| - Loop diuretics | 14 (10.8) |
| - Potassium sparing diuretics | 2 (1.5) |
| - Carbonic anhydrase inhibitors | 1 (0.8) |
| - Osmotic diuretics | 9 (6.9) |
| Non-vitamin K oral anticoagulants | |
| - Apixaban | 3 (2.3) |
| - Rivaroxaban | 2 (1.5) |
| - Dabigatran | 1 (0.8) |
| Class III antiarrhythmics | |
| - Amiodarone | 6 (4.6) |
| Oral antidiabetics | |
| - Biguanide | 8 (6.1) |
| - Sulfonylureas | 2 (1.5) |
| Insulin | 6 (4.6) |
| Alpha-blockers | |
| - Doxazosine | 5 (3.8) |
| Antianginal agents | |
| - Ranolazine | 7 (5.4) |
| Antigout drugs | |
| - Febuxostat | 5 (3.8) |
| Glucocorticoids | |
| - Prednisolone | 1 (0.8) |
| Levothyroxine | 6 (4.6) |
| Heparin | 1 (0.8) |
| Antiepileptic drugs | 1 (0.8) |
| Proton pump inhibitors | |
| - Omeprazole | 14 (10.8) |
| - Pantoprazole | 44 (33.8) |
| - Esomeprazole | 3 (2.3) |
| - Lansoprazole | 1 (0.8) |
| - Rabeprazole | 2 (1.5) |